Silence Therapeutics plc (NASDAQ:SLN) Given Consensus Rating of “Buy” by Brokerages

Silence Therapeutics plc (NASDAQ:SLN) has been given an average rating of “Buy” by the six brokerages that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year is $57.20.

SLN has been the subject of a number of research reports. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research report on Friday, November 15th. Morgan Stanley reissued an “overweight” rating and issued a $49.00 price target on shares of Silence Therapeutics in a research report on Tuesday, October 8th. Jefferies Financial Group initiated coverage on shares of Silence Therapeutics in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price target for the company. Finally, Chardan Capital reissued a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a research report on Thursday, November 14th.

Silence Therapeutics Trading Up 2.9 %

Shares of SLN stock opened at $7.21 on Tuesday. The firm has a fifty day moving average price of $16.68 and a 200 day moving average price of $18.52. The company has a market cap of $215.80 million, a P/E ratio of -4.59 and a beta of 1.30. Silence Therapeutics has a 12 month low of $5.81 and a 12 month high of $27.72.

Institutional Investors Weigh In On Silence Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Lombard Odier Asset Management USA Corp raised its holdings in Silence Therapeutics by 0.7% during the second quarter. Lombard Odier Asset Management USA Corp now owns 2,405,998 shares of the company’s stock worth $45,714,000 after purchasing an additional 17,086 shares in the last quarter. Redmile Group LLC purchased a new position in Silence Therapeutics during the first quarter worth about $43,798,000. Janus Henderson Group PLC raised its holdings in Silence Therapeutics by 32.8% during the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock worth $19,798,000 after purchasing an additional 268,250 shares in the last quarter. Millennium Management LLC raised its holdings in Silence Therapeutics by 91.2% during the second quarter. Millennium Management LLC now owns 782,941 shares of the company’s stock worth $14,876,000 after purchasing an additional 373,523 shares in the last quarter. Finally, Eventide Asset Management LLC purchased a new position in Silence Therapeutics during the third quarter worth about $11,635,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.